{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:03:25Z","timestamp":1793930605481,"version":"4.8.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunotherapy has revolutionized cancer treatment during the last years. Several monoclonal antibodies that are specific for regulatory checkpoint molecules, that is, immune checkpoint inhibitors (ICIs), have been approved and are currently in use for various types of cancer in different lines of treatment. Cancer immunotherapy aims for enhancing the immune response against cancer cells. Despite their high efficacy, ICIs are associated to a new spectrum of adverse events of autoimmune origin, often referred to as immune-related adverse events (irAEs), which limit the utility of these drugs. These irAEs are quite common and can affect almost every organ. The grade of toxicity varies from very mild to life-threatening. The pathophysiological mechanisms behind these events are not fully understood. In this review, we will summarize current evidence specifically regarding the rheumatic irAEs and we will focus on current and future treatment strategies. Treatment guidelines largely support the use of glucocorticoids as first-line therapy, when symptomatic therapy is not efficient, and for more persistent and\/or moderate\/severe degree of inflammation. Targeted therapies are higher up in the treatment pyramid, after inadequate response to glucocorticoids and conventional, broad immunosuppressive agents, and for severe forms of irAEs. However, preclinical data provide evidence that raise concerns regarding the potential risk of impaired antitumoral effect. This potential risk of glucocorticoids, together with the high efficacy and potential synergistic effect of newer, targeted immunomodulation, such as tumor necrosis factor and interleukin-6 blockade, could support a paradigm shift, where more targeted treatments are considered earlier in the treatment sequence.<\/jats:p>","DOI":"10.1007\/s10067-020-05420-w","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T22:02:27Z","timestamp":1601330547000},"page":"1687-1695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors\u2014is it time for a paradigm shift?"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2669-1247","authenticated-orcid":false,"given":"Katerina","family":"Chatzidionysiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matina","family":"Liapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsakonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Gunnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Catrina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"key":"5420_CR1","doi-asserted-by":"publisher","unstructured":"Farkona S, Diamandis EP, Blasutig IM (2016) Cancer immunotherapy: the beginning of the end of cancer? BMC Med. https:\/\/doi.org\/10.1186\/s12916-016-0623-5","DOI":"10.1186\/s12916-016-0623-5"},{"key":"5420_CR2","doi-asserted-by":"publisher","unstructured":"Sharma P, Wagner K, Wolchok JD, Allison JP (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. https:\/\/doi.org\/10.1038\/nrc3153","DOI":"10.1038\/nrc3153"},{"key":"5420_CR3","doi-asserted-by":"publisher","unstructured":"Drake CG, Jaffee E, Pardoll DM (2006) Mechanisms of immune evasion by tumors. Adv Immunol. https:\/\/doi.org\/10.1016\/S0065-2776(06)90002-9","DOI":"10.1016\/S0065-2776(06)90002-9"},{"key":"5420_CR4","doi-asserted-by":"publisher","unstructured":"Yaddanapudi K, Mitchell RA, Eaton JW (2013) Cancer vaccines: looking to the future. Oncoimmunology. https:\/\/doi.org\/10.4161\/onci.23403","DOI":"10.4161\/onci.23403"},{"key":"5420_CR5","doi-asserted-by":"publisher","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science (80- ). https:\/\/doi.org\/10.1126\/science.aar6711","DOI":"10.1126\/science.aar6711"},{"key":"5420_CR6","doi-asserted-by":"publisher","unstructured":"Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 Pathways. Am J Clin Oncol. https:\/\/doi.org\/10.1097\/coc.0000000000000239","DOI":"10.1097\/coc.0000000000000239"},{"key":"5420_CR7","doi-asserted-by":"publisher","unstructured":"Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol. https:\/\/doi.org\/10.1038\/ni0702-611","DOI":"10.1038\/ni0702-611"},{"key":"5420_CR8","doi-asserted-by":"publisher","unstructured":"Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. https:\/\/doi.org\/10.1084\/jem.182.2.459","DOI":"10.1084\/jem.182.2.459"},{"key":"5420_CR9","doi-asserted-by":"publisher","unstructured":"Linsley PS, Bradshaw J, Greene JA, Peach R, Bennett KL, Mittler RS (1996) Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity. https:\/\/doi.org\/10.1016\/S1074-7613(00)80480-X","DOI":"10.1016\/S1074-7613(00)80480-X"},{"key":"5420_CR10","doi-asserted-by":"publisher","unstructured":"Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Immunologic self-tolerance maintained by CD25 + CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. https:\/\/doi.org\/10.1084\/jem.192.2.303","DOI":"10.1084\/jem.192.2.303"},{"key":"5420_CR11","doi-asserted-by":"publisher","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090331","DOI":"10.1146\/annurev.immunol.26.021607.090331"},{"key":"5420_CR12","doi-asserted-by":"publisher","unstructured":"Philips EA, Garcia-Espa\u00f1a A, Tocheva AS, Ahearn IM, Adam KR, Pan R, Mor A, Kong XP, Cresswell P (2020) The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.AC119.011747","DOI":"10.1074\/jbc.AC119.011747"},{"key":"5420_CR13","doi-asserted-by":"publisher","unstructured":"Calles A, Liao X, Sholl LM et al (2015) Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer. J Thorac Oncol. https:\/\/doi.org\/10.1097\/JTO.0000000000000687","DOI":"10.1097\/JTO.0000000000000687"},{"key":"5420_CR14","doi-asserted-by":"publisher","unstructured":"Wherry EJ (2011) T cell exhaustion. Nat Immunol. https:\/\/doi.org\/10.1038\/ni.2035","DOI":"10.1038\/ni.2035"},{"key":"5420_CR15","doi-asserted-by":"publisher","unstructured":"Blank CU, Haining WN, Held W et al (2019) Defining \u2018T cell exhaustion\u2019. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/s41577-019-0221-9","DOI":"10.1038\/s41577-019-0221-9"},{"key":"5420_CR16","doi-asserted-by":"publisher","unstructured":"Youngnak P, Kozono Y, Kozono H et al (2003) Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun. https:\/\/doi.org\/10.1016\/S0006-291X(03)01257-9","DOI":"10.1016\/S0006-291X(03)01257-9"},{"key":"5420_CR17","doi-asserted-by":"publisher","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB (2020) Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12030738","DOI":"10.3390\/cancers12030738"},{"key":"5420_CR18","doi-asserted-by":"publisher","unstructured":"Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH, Calabrese L (2020) Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. https:\/\/doi.org\/10.1038\/s41571-020-0352-8","DOI":"10.1038\/s41571-020-0352-8"},{"key":"5420_CR19","doi-asserted-by":"publisher","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMra1703481","DOI":"10.1056\/NEJMra1703481"},{"key":"5420_CR20","doi-asserted-by":"publisher","unstructured":"Arnaud-Coffin P, Maillet D, Gan HK, Stelmes JJ, You B, Dalle S, P\u00e9ron J (2019) A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.32132","DOI":"10.1002\/ijc.32132"},{"key":"5420_CR21","doi-asserted-by":"publisher","unstructured":"Das S, Johnson DB (2019) Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-019-0805-8","DOI":"10.1186\/s40425-019-0805-8"},{"key":"5420_CR22","doi-asserted-by":"publisher","unstructured":"Calabrese LH, Calabrese C, Cappelli LC (2018) Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol. https:\/\/doi.org\/10.1038\/s41584-018-0074-9","DOI":"10.1038\/s41584-018-0074-9"},{"key":"5420_CR23","doi-asserted-by":"publisher","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Su\u00e1rez-Almazor ME (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Prim. https:\/\/doi.org\/10.1038\/s41572-020-0160-6","DOI":"10.1038\/s41572-020-0160-6"},{"key":"5420_CR24","doi-asserted-by":"publisher","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society Of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"5420_CR25","doi-asserted-by":"publisher","unstructured":"Kostine M, Finckh A, Bingham CO et al (2020) EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217139","DOI":"10.1136\/annrheumdis-2020-217139"},{"key":"5420_CR26","doi-asserted-by":"publisher","unstructured":"Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","DOI":"10.1186\/s40425-017-0300-z"},{"key":"5420_CR27","doi-asserted-by":"publisher","unstructured":"Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdx225","DOI":"10.1093\/annonc\/mdx225"},{"key":"5420_CR28","doi-asserted-by":"publisher","unstructured":"Cappelli LC, Gutierrez AK, Baer AN et al (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209595","DOI":"10.1136\/annrheumdis-2016-209595"},{"key":"5420_CR29","doi-asserted-by":"publisher","unstructured":"Maxwell R, Luksik AS, Garzon-Muvdi T et al (2018) Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. Oncoimmunology. https:\/\/doi.org\/10.1080\/2162402X.2018.1500108","DOI":"10.1080\/2162402X.2018.1500108"},{"key":"5420_CR30","doi-asserted-by":"publisher","unstructured":"Yang H, Xia L, Chen J et al (2019) Stress\u2013glucocorticoid\u2013TSC22D3 axis compromises therapy-induced antitumor immunity. Nat Med. https:\/\/doi.org\/10.1038\/s41591-019-0566-4","DOI":"10.1038\/s41591-019-0566-4"},{"key":"5420_CR31","doi-asserted-by":"publisher","unstructured":"Draghi A, Borch TH, Radic HD, Chamberlain CA, Gokuldass A, Svane IM, Donia M (2019) Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.32080","DOI":"10.1002\/ijc.32080"},{"key":"5420_CR32","doi-asserted-by":"publisher","unstructured":"Falc\u00f3n-Beas C, Tittarelli A, Mora-Bau G et al (2019) Dexamethasone turns tumor antigen-presenting cells into tolerogenic dendritic cells with T cell inhibitory functions. Immunobiology. https:\/\/doi.org\/10.1016\/j.imbio.2019.05.011","DOI":"10.1016\/j.imbio.2019.05.011"},{"key":"5420_CR33","doi-asserted-by":"publisher","unstructured":"Mitchell EL, Lau PKH, Khoo C et al (2018) Rheumatic immune-related adverse events secondary to anti\u2013programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series. Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.027","DOI":"10.1016\/j.ejca.2018.09.027"},{"key":"5420_CR34","doi-asserted-by":"publisher","unstructured":"Garant A, Guilbault C, Ekmekjian T, Greenwald Z, Murgoi P, Vuong T (2017) Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: a systematic review. Crit Rev Oncol Hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.10.009","DOI":"10.1016\/j.critrevonc.2017.10.009"},{"key":"5420_CR35","doi-asserted-by":"publisher","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1507643","DOI":"10.1056\/NEJMoa1507643"},{"key":"5420_CR36","doi-asserted-by":"publisher","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1606774","DOI":"10.1056\/NEJMoa1606774"},{"key":"5420_CR37","doi-asserted-by":"publisher","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"5420_CR38","doi-asserted-by":"publisher","unstructured":"Arbour KC, Mezquita L, Long N et al (2018) Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2018.79.0006","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"5420_CR39","doi-asserted-by":"publisher","unstructured":"Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM (2019) Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.19.00189","DOI":"10.1200\/JCO.19.00189"},{"key":"5420_CR40","doi-asserted-by":"publisher","unstructured":"Weber JS, Antonia SJ, Topalian SL, Schadendorf D, Larkin JMG, Sznol M, Liu HY, Waxman I, Robert C (2015) Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.9018","DOI":"10.1200\/jco.2015.33.15_suppl.9018"},{"key":"5420_CR41","doi-asserted-by":"publisher","unstructured":"Chu WM (2013) Tumor necrosis factor. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2012.10.014","DOI":"10.1016\/j.canlet.2012.10.014"},{"key":"5420_CR42","doi-asserted-by":"publisher","unstructured":"Monaco C, Nanchahal J, Taylor P, Feldmann M (2015) Anti-TNF therapy: past, present and future. Int Immunol. https:\/\/doi.org\/10.1093\/intimm\/dxu102","DOI":"10.1093\/intimm\/dxu102"},{"key":"5420_CR43","doi-asserted-by":"publisher","unstructured":"Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, Collins M, Chaput N, Robert C, Carbonnel F (2018) Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2018-316948","DOI":"10.1136\/gutjnl-2018-316948"},{"key":"5420_CR44","doi-asserted-by":"publisher","unstructured":"Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M (2019) Concurrent therapy with immune checkpoint inhibitors and TNF\u03b1 blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-019-0711-0","DOI":"10.1186\/s40425-019-0711-0"},{"key":"5420_CR45","doi-asserted-by":"publisher","unstructured":"Johnson DH, Zobniw CM, Trinh VA et al (2018) Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-018-0412-0","DOI":"10.1186\/s40425-018-0412-0"},{"key":"5420_CR46","doi-asserted-by":"publisher","unstructured":"Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. https:\/\/doi.org\/10.1038\/ncprheum0338","DOI":"10.1038\/ncprheum0338"},{"key":"5420_CR47","doi-asserted-by":"publisher","unstructured":"Gabay C (2006) Interleukin-6 and chronic inflammation. Arthritis Res Ther. https:\/\/doi.org\/10.1186\/ar1917","DOI":"10.1186\/ar1917"},{"key":"5420_CR48","doi-asserted-by":"publisher","unstructured":"Maini RN, Taylor PC, Szechinski J et al (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. https:\/\/doi.org\/10.1002\/art.22033","DOI":"10.1002\/art.22033"},{"key":"5420_CR49","doi-asserted-by":"publisher","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(08)60453-5","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"5420_CR50","doi-asserted-by":"publisher","unstructured":"Genovese MC, McKay JD, Nasonov EL, Mysler EF, Da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug the. Arthritis Rheum https:\/\/doi.org\/10.1002\/art.23940","DOI":"10.1002\/art.23940"},{"key":"5420_CR51","doi-asserted-by":"publisher","unstructured":"Burmester GR, Rubbert-Roth A, Cantagrel A et al (2014) A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid art. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203523","DOI":"10.1136\/annrheumdis-2013-203523"},{"key":"5420_CR52","doi-asserted-by":"publisher","unstructured":"Stroud CRG, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, Cherukuri S, Parent T, Hardin J, Walker P (2019) Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. https:\/\/doi.org\/10.1177\/1078155217745144","DOI":"10.1177\/1078155217745144"},{"key":"5420_CR53","doi-asserted-by":"publisher","unstructured":"Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, Johnson DH, Uemura M, Diab A (2017) Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211560","DOI":"10.1136\/annrheumdis-2017-211560"},{"key":"5420_CR54","doi-asserted-by":"publisher","unstructured":"Braaten TJ, Brahmer JR, Forde PM et al (2019) Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216109","DOI":"10.1136\/annrheumdis-2019-216109"},{"key":"5420_CR55","doi-asserted-by":"publisher","unstructured":"Bertrand F, Montfort A, Marcheteau E et al (2017) TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-017-02358-7","DOI":"10.1038\/s41467-017-02358-7"},{"key":"5420_CR56","doi-asserted-by":"publisher","unstructured":"Perez-Ruiz E, Minute L, Otano I et al (2019) Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. https:\/\/doi.org\/10.1038\/s41586-019-1162-y","DOI":"10.1038\/s41586-019-1162-y"},{"key":"5420_CR57","doi-asserted-by":"publisher","unstructured":"Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, Senju S, Ihn H, Nishimura Y, Oshiumi H (2018) Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0118","DOI":"10.1158\/0008-5472.CAN-18-0118"},{"key":"5420_CR58","doi-asserted-by":"publisher","unstructured":"Salem JE, Allenbach Y, Kerneis M (2019) Abatacept for severe immune checkpoint inhibitor\u2013associated myocarditis. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMc1901677","DOI":"10.1056\/NEJMc1901677"},{"key":"5420_CR59","doi-asserted-by":"publisher","unstructured":"Heim MH (1999) The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res. https:\/\/doi.org\/10.3109\/10799899909036638","DOI":"10.3109\/10799899909036638"},{"key":"5420_CR60","doi-asserted-by":"publisher","unstructured":"Darnell JE, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (80- ). https:\/\/doi.org\/10.1126\/science.8197455","DOI":"10.1126\/science.8197455"},{"key":"5420_CR61","doi-asserted-by":"publisher","unstructured":"Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/nri1604","DOI":"10.1038\/nri1604"},{"key":"5420_CR62","doi-asserted-by":"publisher","unstructured":"Karachaliou N, Gonzalez-Cao M, Crespo G et al (2018) Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/1758834017749748","DOI":"10.1177\/1758834017749748"},{"key":"5420_CR63","doi-asserted-by":"publisher","unstructured":"Lu C, Talukder A, Savage NM, Singh N, Liu K (2017) JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology. https:\/\/doi.org\/10.1080\/2162402X.2017.1291106","DOI":"10.1080\/2162402X.2017.1291106"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05420-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05420-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05420-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T01:53:06Z","timestamp":1632793986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05420-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5420"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05420-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"10 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KC has received consultancy fees from Eli Lilly, AbbVie and Pfizer. ML: none. GT: none. IG: none. AC: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}